FDA Inspection 1023507 — Oklahoma Blood Institute
The FDA completed an inspection of Oklahoma Blood Institute on Jun 20, 2017 in Oklahoma City, OK. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Jun 20, 2017
- Fiscal Year
- 2017
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Oklahoma City, OK (United States)